Blog

Immunoinformatics merges bioinformatics and immunology. Biointron applies computational tools to accelerate antibody discovery and vaccine development.

Antibody glycosylation affects stability and function. Biointron explores how sugar modifications influence efficacy, safety, and therapeutic performance.

In vitro display technologies enable protein and antibody selection. Biointron highlights methods like phage, yeast, and ribosome display that drive discovery.

Chimeric antibodies blend murine variable regions with human constant domains. Biointron explains their design, benefits, and role in modern therapeutics.

AbDrop™ and HUGO-Ab™ accelerate discovery. Biointron demonstrates how these platforms cut timelines by delivering diverse, high-affinity antibodies faster.

Chimeric antibodies marked a milestone in drug development. Biointron reviews their creation and impact as a foundation for today’s therapeutic antibodies.

Bispecific antibodies fight cancer via unique mechanisms. Biointron highlights how bsAbs target multiple pathways to expand therapeutic impact.

Discovery on Target 2024 in Boston highlighted drug discovery. Biointron shares event insights advancing antibody therapeutics and translational science.

ADCs and checkpoint inhibitors create synergy in oncology. Biointron explains how combining these modalities improves precision and patient outcomes.

Computational antibody design accelerates discovery. Biointron applies AI-driven tools to model, optimize, and improve antibody candidates for therapy.

High-throughput screening rapidly evaluates compounds. Biointron integrates HTS to identify promising leads and guide efficient antibody development.

Next-generation sequencing enables large-scale DNA and RNA analysis. Biointron applies NGS to support antibody discovery and accelerate therapeutic research.